Zhang Linchao, Yang Manli, Ji Yishun, Xiao Kefeng, Shi Jinsheng, Wang Lili
College of Chemistry and Pharmaceutical Sciences, Qingdao Agricultural University, Qingdao 266109, China.
Biomater Sci. 2021 Mar 21;9(6):2124-2136. doi: 10.1039/d0bm01876g. Epub 2021 Jan 25.
Neoadjuvant chemotherapy for the treatment of breast cancer can provide the option of surgery for patients with a large tumor mass or increase the rate of breast conservation. However, some patients are not sensitive to chemotherapeutic drugs, and therefore this may cause them to miss their optimal chance for surgery. Herein, photodynamic therapy (PDT) was chosen instead of chemotherapy as a neoadjuvant treatment for breast cancer because of its effectiveness against different cancer cells and the lack of side effects in normal tissues. Considering the hypoxic environment of tumors and the tissue penetration depth, a heterojunction ZnGeO:Mn/g-CN was designed and combined with upconversion materials NaYF:Yb, Tm and hyaluronic acid to form a NaYF:Yb, Tm/ZnGeO:Mn/g-CN@HA (UZC@HA) photosensitizer. After intratumoral administration using a thermosensitive hydrogel as a carrier, under a 980 nm laser, UZC@HA can generate holes and electrons to oxidize water to form a hydroxyl radical (˙OH) and react with O to produce the superoxide ion (˙O), respectively. The thermosensitive hydrogel not only supplies water, but also ensures the high loading capacity of UZC@HA. HA on the UZC can bind specifically with CD44R-overexpressing tumor cells and help the photosensitizer to target tumor sites. Thus, near infrared (NIR) mediated oxygen-independent PDT can be realized. After 12 d of treatment, the tumor mass was significantly reduced and no side effects in normal tissues were observed. Our work shows the potential of the NIR mediated heterojunction UZC@HA to act as a photosensitizer for neoadjuvant PDT in breast cancer and may open a new avenue for exploration of PDT and provide more options for breast cancer patients.
新辅助化疗用于治疗乳腺癌,可为肿瘤体积较大的患者提供手术选择,或提高保乳率。然而,一些患者对化疗药物不敏感,因此这可能导致他们错过最佳手术时机。在此,由于光动力疗法(PDT)对不同癌细胞有效且对正常组织无副作用,故而被选作乳腺癌的新辅助治疗方法替代化疗。考虑到肿瘤的缺氧环境和组织穿透深度,设计了一种异质结ZnGeO:Mn/g-CN,并将其与上转换材料NaYF:Yb、Tm以及透明质酸相结合,形成一种NaYF:Yb、Tm/ZnGeO:Mn/g-CN@HA(UZC@HA)光敏剂。以热敏水凝胶为载体进行瘤内给药后,在980 nm激光照射下,UZC@HA可产生空穴和电子,将水氧化形成羟基自由基(˙OH),并分别与O反应生成超氧离子(˙O)。热敏水凝胶不仅提供水分,还确保了UZC@HA的高负载量。UZC上的HA可与过表达CD44R的肿瘤细胞特异性结合,帮助光敏剂靶向肿瘤部位。因此,可实现近红外(NIR)介导的不依赖氧气的光动力疗法。治疗12天后,肿瘤体积显著减小,且未观察到正常组织出现副作用。我们的工作表明,近红外介导的异质结UZC@HA有潜力作为乳腺癌新辅助光动力疗法中的光敏剂,可能为光动力疗法的探索开辟一条新途径,并为乳腺癌患者提供更多选择。